Stemedica Cell Technologies is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. The Stemedica’s products are also used by research institutions and hospitals for pre-clinical and clinical (human) trial activities. Under the auspices of the FDA and other international regulatory institutions, Stemedica is developing additional clinical trials using its adult, allogeneic stem cells for other medical indications.